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PURPOSE. To describe the clinical and genetic spectrum of RP1-associated retinal dystrophies.
METHODS. In this multicenter case series, we included 22 patients with RP1-associated retinal
dystrophies from 19 families from The Netherlands and Japan. Data on clinical characteristics,
visual acuity, visual field, ERG, and retinal imaging were extracted from medical records over a
mean follow-up of 8.1 years.
RESULTS. Eleven patients were diagnosed with autosomal recessive macular dystrophy (arMD) or
autosomal recessive cone-rod dystrophy (arCRD), five with autosomal recessive retinitis
pigmentosa (arRP), and six with autosomal dominant RP (adRP). The mean age of onset was
40.3 years (range 14–56) in the patients with arMD/arCRD, 26.2 years (range 18–40) in adRP, and
8.8 years (range 5–12) in arRP patients. All patients with arMD/arCRD carried either the
hypomorphic p.Arg1933* variant positioned close to the C-terminus (8 of 11 patients) or a
missense variant in exon 2 (3 of 11 patients), compound heterozygous with a likely deleterious
frameshift or nonsense mutation, or the p.Gln1916* variant. In contrast, all mutations identified in
adRP and arRP patients were frameshift and/or nonsense variants located far from the C-terminus.
CONCLUSIONS. Mutations in the RP1 gene are associated with a broad spectrum of progressive
retinal dystrophies. In addition to adRP and arRP, our study provides further evidence that
arCRD and arMD are RP1-associated phenotypes as well. The macular involvement in patients
with the hypomorphic RP1 variant suggests that macular function may remain compromised
if expression levels of RP1 do not reach adequate levels after gene augmentation therapy.
Keywords: RP1, phenotypic spectrum, macular dystrophy, cone-rod dystrophy, retinitis
pigmentosa
Retinitis pigmentosa (RP) encompasses a heterogeneousgroup of inherited retinal dystrophies characterized by rod
photoreceptor degeneration that precedes cone photoreceptor
degeneration. The RP1 gene is one of the more than 80 genes
associated with RP. Besides RP1, seven other RP genes—BEST1,
NR2E3, NRL, RHD12, RHO, RPE65, and SAG—have been
associated with both autosomal dominant and autosomal
recessive modes of inheritance.1 In general, RP patients with
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an autosomal recessive inheritance pattern have a more severe
disease course compared with patients with autosomal
dominant RP (adRP). This also applies to patients with RP1-
associated RP: autosomal recessive RP1 patients generally have
a lower age of onset compared with autosomal dominant RP1
patients, as well as a worse long-term prognosis with respect to
retaining central vision due to the occurrence of early macular
atrophy or cystoid macular edema.1,2
The RP1 gene, mapped to chromosome 8q12.1, contains
four exons, three of which are coding, and encodes a
photoreceptor-specific microtubule-associated protein that
plays a vital role in the architecture of both rod and cone
photoreceptor outer segments.3,4 RP1 is located at the
photoreceptor axoneme, where it links outer segment discs
to the axonemal microtubules, and thereby regulates the
length and stability of the axoneme.5 The interaction with the
microtubules is mediated primarily by two doublecortin (DCX)
domains encoded by exons 2 and 3.5 In addition, RP1 contains
a third putative domain, between amino acid residues 486 and
635, that shares homology with the Drosophila melanogaster
bifocal (BIF) protein, which is required for normal photore-
ceptor morphogenesis.6 RP1 mutations that are known to
cause adRP are clustered in a relatively small region in exon 4
between amino acid residues 500 and 1053,7 and result in the
production of a truncated protein with a presumed dominant-
negative activity.8 In contrast, most mutations located more
toward the N- or C-terminus of RP1 result in autosomal
recessive RP (arRP).7
In 2016, Ellingford et al.9 identified compound heterozy-
gous mutations in RP1 (i.e., p.Tyr41His and p.Leu172Arg) in a
patient diagnosed with macular dystrophy (MD)/presumed
Stargardt disease. However, because this new genotype-
phenotype correlation was identified in only a single family,
they concluded that reevaluation of the clinical phenotype was
warranted.9 Knowledge about the entire disease spectrum
associated with certain genes is important, particularly in view
of novel therapeutic options, as the prognosis and disease
course between phenotypes may differ markedly. In this study,
we report patients diagnosed with MD and cone-rod dystrophy
(CRD) in addition to patients with RP, and expand the clinical
spectrum associated with mutations in the RP1 gene.
METHODS
Patients
Twenty-two patients (19 families) with a retinal dystrophy and
mutations in the RP1 gene were clinically examined at the
Radboud university medical center in Nijmegen, The Nether-
lands (families A, B, M, N , P, and Q); the Tohoku University
Graduate School of Medicine in Sendai, Japan (families C–E, J
and L); the Kyushu University Hospital, Fukuoka, Japan
(families F and K); the Yuko Wada Eye Clinic, Sendai, Japan
(family G); and the Amsterdam UMC, The Netherlands (families
H, I, O, R and S). The genetic evaluation was performed
between June 2013 and May 2018. Informed consent was
obtained from all patients before data collection and additional
ophthalmic examinations. The study adhered to the tenets of
the Declaration of Helsinki, and was approved by the local
ethics committees.
Genetic Analysis
In all families, genomic DNA was extracted from peripheral
lymphocytes according to standard procedures. The genetic
data of the Japanese patients was obtained in context of
another study.10 In short, whole exome sequencing was
performed in patients A-II:2, A-II:4, A-II:5, B-II:8, H-II:2, I-II:2,
M-II:2, P-II:13, and Q-III:4. The exome data were analyzed using
a vision gene panel consisting of 220 (patients H-II:2 and I-II:2),
342 (patient P-II:13), 366 (patient B-II:7), and 395 genes
(patients M-II:2 and Q-III:4) or without the use of a gene filter
(family A). See Supplementary Table S1 for an overview of the
genes included in these panels. Targeted panel sequencing
covering 256 (patient R-IV:2) or 266 vision genes (patients O-
II:1 and S-III:4) was performed in a certified DNA diagnostic
laboratory, with additional Sanger sequencing for all areas with
a coverage below 30 reads (Supplementary Table S1).
Mutational screening in patient N-III:9 was performed using
an arrayed primer extension microarray for adRP (containing
414 variants in 16 genes), according to a previously described
protocol.11 All variants detected by microarray analysis were
verified by direct sequencing. Patients C to G and J to L had
their RP1 open reading frame screened by means of Sanger
sequencing as previously reported.10 In addition, molecular
inversion probes were used to exclude variants in 109 other
inherited retinal dystrophy genes in patients C to F, J, and K,10
and targeted resequencing containing 83 nonsyndromic RP
genes was performed in patient L-II:2 (Supplementary Table
S1). The pathogenicity of novel missense variants was assessed
combining cosegregation analysis and in silico prediction tools,
including SIFT and Polyphen-2, and by using the PhyloP, CADD-
PHRED, and Grantham scores. For an extensive description of
the genetic analysis, see Supplement 1.
Clinical Evaluation
Clinical data were obtained from the medical records of the
patients. In addition, three patients (family A) were reevaluated
after the identification of the causative RP1 mutations. We
performed a detailed ophthalmic examination, which included
visual acuity testing, slit-lamp biomicroscopy, and detailed
ophthalmoscopy. Most patients also underwent conventional
fundus photography and/or ultra-widefield fundus imaging
(Optos P200Tx; Optos, Dunfermline, UK), Goldmann perim-
etry, as well as spectral-domain optical coherence tomography
(SD-OCT) using a confocal scanning laser ophthalmoscope
(Spectralis HRAþOCT; Heidelberg Engineering, Heidelberg,
Germany; Cirrus; Carl Zeiss Meditec, Inc., Dublin, CA; or
Topcon 3D OCT-2000; Topcon, Inc, Tokyo, Japan ). Fundus
autofluorescence (FAF) imaging was performed using the
Spectralis HRAþOCT 308 3 308 field of view centered on the
macula,12 or the 2008 field of view from the ultra-widefield
imaging device. All patients underwent full-field ERG, and
multifocal electroretinography (mfERG) was performed in
patients B-II:8, C-II:2, D-II:1, and E-II:2. Electrophysiological
recordings were performed according to the International
Society for Clinical Electrophysiology of Vision guidelines and
assessed by applying local standard values.13,14
Patients were diagnosed based on their (initial) symptoms,
fundus abnormalities, ERG findings, and overall course of the
disease. They received the diagnosis MD if they experienced
central vision loss without symptoms of night blindness,
ophthalmoscopy and multimodal imaging revealed no signs of
peripheral involvement, in the presence of an intact peripheral
visual field, normal to marginally abnormal scotopic ERG
responses, and normal to moderately reduced photopic ERG
responses. Patients with a panretinal phenotype received the
diagnosis CRD or RP, depending on which photoreceptor
function was affected first. CRD was diagnosed when the onset
of loss of central vision preceded that of night blindness,
presence of a central scotoma, no or mild constriction of the
visual field, and reduced ERG responses in a cone-rod pattern.
Patients were diagnosed with RP when they presented with
night blindness, constriction of the visual field, and reduced
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ERG responses in a rod-cone pattern. The clinical distinction
between MD and CRD, however, can be difficult and is
sometimes arbitrary in view of the significant clinical overlap.
In addition, in individual MD patients the MD may progress in a
more generalized disorder that fits the criteria of CRD. In the
present study, we therefore grouped the MD and CRD
spectrum into a single category for further analysis.
RESULTS
Genetic Findings
Genetic analysis detected 16 unique variants in the RP1 gene,
including six newly identified variants, in the 19 families (Fig.
1).10 The novel variants included five nonsense and frameshift
mutations, as well as the p.Val190Gly missense variant that is
likely pathogenic according to the guideline proposed by the
American College of Medical Genetics and Genomics.15 The
variant segregates with the disease (M8, family H), affects a
highly conserved amino acid that is located in the DCX
domain, is extremely rare in the gnomAD database (1/249046),
and is predicted to be pathogenic with a high Grantham score
(109/215) and CADD-PRHED score (22.2) including a high SIFT
(pathogenic) and PolyPhen-2 score (probably damaging).
Heterozygous variants in other inherited retinal dystrophy
genes are listed in Supplementary Table S2.
Notably, compound heterozygous mutations were identified
in all patients with autosomal recessive MD (arMD)/autosomal
recessive CRD (arCRD). In particular, the p.Arg1933* mutation,
which was identified in a compound heterozygous state with
another nonsense or frameshift mutation in six of eight families
with arMD/arCRD, from both East Asian and Caucasian origins
(Fig. 1). The remaining two families with arMD/arCRD (families
B and H) carried a heterozygous missense mutation
(p.Phe180Cys or p.Val190Gly) located in exon 2, in the region
that encodes the DCX domain, together with a frameshift
mutation on the second allele. Families with an identical
combination of mutations were identified; p.Arg1933* in
combination with p.Tyr1352Alafs*9 was previously identified
in four families of East Asian origin (families C– F).10
In contrast, in five of six families with arRP, homozygous
nonsense or frameshift variants were identified. Remarkably,
the p.Tyr1352Alafs*9 mutation that was found in patients with
arMD/arCRD in combination with p.Arg1933* in families C to F,
was identified in a homozygous state in two families with arRP
(families J and K), as described.10 In addition, the p.Pro124A-
lafs*20 mutation that causes arMD/arCRD in combination with
the p.Val190Gly missense mutation in patient H, was also
identified in a homozygous state in arRP family N.
Clinical Findings
An overview of the individual clinical characteristics of the
patients with an RP1 mutation is provided in the Table. The
clinical characteristics stratified by phenotype are provided in
Supplementary Table S3. Of the 22 patients, 11 patients (7
arMD and 4 arCRD patients from eight families) were
diagnosed with arMD/arCRD, 5 patients (five families) with
arRP, and 6 patients (six families) with adRP. Patient B-II:8 was
initially diagnosed with a hydroxychloroquine-associated mac-
ulopathy as she received treatment with hydroxychloroquine
for rheumatoid arthritis. The correct diagnosis of RP1-
associated MD was made based on her clinical presentation
that was atypical for hydroxychloroquine maculopathy, the
low cumulative dose of 280 g of hydroxychloroquine, and an
affected sister free of the medication. Subsequent molecular
genetic testing revealed compound heterozygous mutations in
the RP1 gene in both of them.
Patients With arMD/arCRD
The patients with arMD/arCRD presented the latest of the
three phenotypes (mean age of onset 40.3 years; SD 13.1 years,
range 14–56 years), although they showed overlap in age at
onset with the adRP patients (mean 26.2 years, SD 8.2 years,
range 18–40 years, P¼ 0.025) (Supplementary Table S3). Their
initial symptom was a decrease in visual acuity or metamor-
phopsia, sometimes accompanied by photophobia (patient C-
II:2) or night blindness (patient F-II:3 and G-II:2). With
progression of the disease, 8 of 11 patients developed
photophobia. All patients were myopic (range of spherical
equivalents: 9.50 diopters [D] to 0.25 D). Biomicroscopy
revealed several types of lens opacities in 6 of 11 patients of
whom patient F-II:3 underwent cataract extraction at the age of
61 years (Table, Supplementary Table S3). The course of the
visual acuity for each patient is represented in Figure 2. Ten
patients revealed mild to moderate visual acuity impairment
during working life, which eventually led to acuity levels of 20/
400 in the eighth decade (patient A-II:2). However, patient C-
II:2 already had a visual acuity of 20/400 at the age of 41 years.
Visual field testing revealed an absolute central scotoma,
except for a paracentral scotoma in the left eye of patient B-II:8
(age 55 years), and a central, relative scotoma in patient B-II:3
(age 64 years). In addition, the visual field was mildly
constricted in patients B-II:3, F-II:3, and G-II:2.
Ophthalmoscopy showed RPE alterations or atrophy in the
macula (Table, Fig. 3). Attenuation of the retinal vessels was
present in patients A-II:4, B-II:3, F-II:3, and G-II:2, focal bone
spicule pigmentations were observed in patient F-II:3, and a
single nummular pigmentation in patient G-II:2. A bull’s eye
maculopathy was noticed in the left eye of patient B-II:8 (age
55) and both eyes of patient E-II:2 at the most recent
examination. In patient A-II:5, the bull’s eye maculopathy had
progressed to macular atrophy with foveal involvement (Fig.
4). A posterior staphyloma was visible in patient A-II:2 with
spherical equivalents of 8.38/8.00 D. SD-OCT images
revealed loss of the outer retinal layers in the macula, with
sparing of the foveal photoreceptors in the patients with a
bull’s eye maculopathy and the left eye of patient B-II:3 (age
64), in which the photoreceptors and RPE at the fovea were
preserved in a foveal sparing-like pattern (Fig. 3F). The right
eye of patient B-II:3 initially showed foveal sparing at the age of
56 years, although shortly afterward the foveal cells degener-
ated as well, with a corresponding loss in visual acuity. FAF
imaging showed a round to oval zone of reduced FAF or a
speckled pattern of alternating normal and decreased FAF,
bordered by a band of increased FAF (Fig. 3); except for patient
E:II-2, in whom an oval zone of increased FAF was visible
without a reduced autofluorescence signal. FAF images of
patients F-II:3 and G-II:2 were not acquired. Full-field ERG
ranged from normal rod and cone responses to patients in
whom both cone and rod responses were moderately or
severely reduced (Table). The mfERG, performed in patients B-
II:8, C-II:2, D-II:1, and E-II:2, was severely reduced in all
patients except for patient B-II:8 in whom a decreased
response in the parafoveal ring was visible in the right eye
and moderately reduced responses in the left eye.
Autosomal Recessive RP
The arRP patients were affected at the earliest age, with a mean
age of onset of 8.8 years and an onset at the age of only 5 years
in the youngest patient (SD 2.8; range 5–12 years; Supplemen-
tary Table S3). The initial symptom in the arRP patients was
Macular and Cone-Rod Dystrophy Caused by RP1 Mutations IOVS j March 2019 j Vol. 60 j No. 4 j 1194
Downloaded from iovs.arvojournals.org on 05/27/2020
FIGURE 1. Pedigrees of the families included in this study. Squared boxes indicate men, circles indicate women, filled symbols represent affected
persons, and unfilled symbols represent unaffected persons. The plus sign denotes the wild-type allele, and the arrow indicates the proband of the
family. Double lines point out consanguineous marriages, the number above the lines indicates the degree of consanguinity. Where relatives were
available (families A, B, C, D, H, I, and N), the mutations segregate with the disease. Families C to F, J, and K have previously been described by
Nikopoulos et al.10 §Novel variants.
Macular and Cone-Rod Dystrophy Caused by RP1 Mutations IOVS j March 2019 j Vol. 60 j No. 4 j 1195
Downloaded from iovs.arvojournals.org on 05/27/2020
T
A
B
L
E
.
C
li
n
ic
al
F
e
at
u
re
s
o
f
P
at
ie
n
ts
C
ar
ry
in
g
P
at
h
o
ge
n
ic
M
u
ta
ti
o
n
s
in
R
P
1
ID
/S
e
x
/A
g
e
o
f
O
n
se
t,
y
/A
g
e
R
a
c
e
In
it
ia
l
S
y
m
p
to
m
V
is
u
a
l
A
c
u
it
y
R
E
L
E
S
E
R
†
R
E
L
E
L
e
n
s
S
ta
tu
s
O
p
h
th
a
lm
o
sc
o
p
y
R
e
su
lt
s
E
R
G
R
e
su
lt
s
G
o
ld
m
a
n
n
P
e
ri
m
e
tr
y
D
x
M
u
ta
ti
o
n
(s
)
S
c
o
t
P
h
o
t
M
D
/C
R
D
A
-I
I:
2
/F
/3
1
/7
7
C
au
c
as
ia
n
D
e
c
re
as
e
in
V
A
/
m
e
ta
m
o
rp
h
o
p
si
a
2
0
/4
0
0
2
0
/4
0
0
8
.3
8
8
.0
0
M
il
d
P
SC
,
se
v
e
re
c
o
rt
ic
al
an
d
n
u
c
le
ar
c
at
ar
ac
t
W
e
ll
-d
e
m
ar
c
at
e
d
ar
e
a
o
f
c
e
n
tr
al
an
d
p
e
ri
p
ap
il
la
ry
ch
o
ri
o
re
ti
n
al
at
ro
p
h
y.
N
o
rm
al
as
p
e
c
t
o
f
re
ti
n
al
ve
ss
e
ls
an
d
o
p
ti
c
d
is
c
.
P
o
st
e
ri
o
r
st
ap
h
yl
o
m
a
L
E
>
R
E
.
SN
M
R
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.G
ln
1
9
1
6
*
p
.A
rg
1
9
3
3
*
A
-I
I:
4
/M
/5
0
/6
9
C
au
c
as
ia
n
D
e
c
re
as
e
in
V
A
2
0
/2
0
0
2
0
/2
0
0
2
.0
0
2
.0
0
C
o
rt
ic
al
an
d
n
u
c
le
ar
c
at
ar
ac
t
W
e
ll
-d
e
m
ar
c
at
e
d
ar
e
a
o
f
c
e
n
tr
al
an
d
p
e
ri
p
ap
il
la
ry
ch
o
ri
o
re
ti
n
al
at
ro
p
h
y.
N
o
rm
al
o
p
ti
c
d
is
c
,
m
il
d
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
in
s.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
N
N
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.G
ln
1
9
1
6
*
p
.A
rg
1
9
3
3
*
A
-I
I:
5
/F
/4
5
/6
7
C
au
c
as
ia
n
M
e
ta
m
o
rp
h
o
p
si
a
2
0
/5
0
0
2
0
/6
3
5
.5
0
4
.8
8
C
o
rt
ic
al
an
d
n
u
c
le
ar
c
at
ar
ac
t,
m
il
d
P
SC
M
ac
u
la
r
an
d
p
e
ri
p
ap
il
la
ry
at
ro
p
h
y.
N
o
rm
al
as
p
e
c
t
o
f
v
as
c
u
la
tu
re
an
d
o
p
ti
c
d
is
c
.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
N
N
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.G
ln
1
9
1
6
*
p
.A
rg
1
9
3
3
*
B
-I
I:
3
/F
/5
6
/6
4
C
au
c
as
ia
n
D
e
c
re
as
e
in
V
A
2
0
/1
1
0
2
0
/1
2
5
2
.0
0
1
.0
0
M
il
d
c
o
rt
ic
al
an
d
n
u
c
le
ar
c
at
ar
ac
t
Se
ve
re
at
ro
p
h
y
an
d
g
li
o
si
s
in
th
e
m
ac
u
la
B
E
,
w
it
h
fo
v
ea
l
sp
ar
in
g
in
th
e
L
E
.
P
e
ri
p
ap
il
la
ry
at
ro
p
h
y,
at
te
n
u
at
e
d
ve
ss
e
ls
,
an
d
n
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
SR
SR
Sl
ig
h
tl
y
c
o
n
st
ri
c
te
d
V
F
(R
E
>
L
E
),
m
o
d
e
ra
te
c
e
n
tr
al
se
n
si
ti
v
it
y
lo
ss
ar
C
R
D
p
.P
h
e
1
8
0
C
ys
p
.H
is
1
4
1
4
G
ln
fs
*5
B
-I
I:
8
/F
/5
5
/5
5
C
au
c
as
ia
n
D
e
c
re
as
e
in
V
A
2
0
/4
0
0
2
0
/1
7
1
.0
0
0
.5
0
C
le
ar
W
e
ll
-d
e
m
ar
c
at
e
d
ar
e
a
o
f
m
ac
u
la
r
at
ro
p
h
y
in
th
e
R
E
,
an
d
R
P
E
al
te
ra
ti
o
n
s
w
it
h
a
b
u
ll
’s
e
ye
c
o
n
fi
g
u
ra
ti
o
n
in
th
e
L
E
.
N
o
rm
al
as
p
e
c
t
o
f
th
e
re
ti
n
al
ve
ss
e
ls
an
d
o
p
ti
c
d
is
c
.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
N
SN
C
e
n
tr
al
sc
o
to
m
a
R
E
,
p
ar
ac
e
n
tr
al
sc
o
to
m
a
L
E
ar
M
D
p
.P
h
e
1
8
0
C
ys
p
.H
is
1
4
1
4
G
ln
fs
*5
C
-I
I:
2
/F
/2
5
/4
1
E
as
t
A
si
an
D
e
c
re
as
e
in
V
A
/
p
h
o
to
p
h
o
b
ia
2
0
/5
0
0
2
0
/4
0
0
9
.0
0
9
.5
0
C
le
ar
R
P
E
al
te
ra
ti
o
n
s
in
th
e
m
ac
u
la
w
it
h
sm
al
l,
p
ar
af
o
ve
al
ar
e
as
o
f
at
ro
p
h
y.
N
o
rm
al
as
p
e
c
t
o
f
th
e
o
p
ti
c
d
is
c
an
d
re
ti
n
al
v
es
se
ls
.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
SN
M
R
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.A
rg
1
9
3
3
*
p
.T
y
r1
3
5
2
A
la
fs
*9
D
-I
I:
1
/M
/4
4
/5
4
E
as
t
A
si
an
D
e
c
re
as
e
in
V
A
2
0
/2
2
2
2
0
/1
3
3
2
.5
0
2
.5
0
C
le
ar
R
P
E
al
te
ra
ti
o
n
s
in
th
e
m
ac
u
la
w
it
h
sm
al
l,
p
ar
af
o
ve
al
ar
e
as
o
f
R
P
E
at
ro
p
h
y.
P
e
ri
p
ap
il
la
ry
at
ro
p
h
y.
N
o
rm
al
as
p
e
c
t
o
f
th
e
o
p
ti
c
d
is
c
an
d
re
ti
n
al
ve
ss
e
ls
.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
SN
M
R
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.A
rg
1
9
3
3
*
p
.T
y
r1
3
5
2
A
la
fs
*9
Macular and Cone-Rod Dystrophy Caused by RP1 Mutations IOVS j March 2019 j Vol. 60 j No. 4 j 1196
Downloaded from iovs.arvojournals.org on 05/27/2020
T
A
B
L
E
.
C
o
n
ti
n
u
e
d
ID
/S
e
x
/A
g
e
o
f
O
n
se
t,
y
/A
g
e
R
a
c
e
In
it
ia
l
S
y
m
p
to
m
V
is
u
a
l
A
c
u
it
y
R
E
L
E
S
E
R
†
R
E
L
E
L
e
n
s
S
ta
tu
s
O
p
h
th
a
lm
o
sc
o
p
y
R
e
su
lt
s
E
R
G
R
e
su
lt
s
G
o
ld
m
a
n
n
P
e
ri
m
e
tr
y
D
x
M
u
ta
ti
o
n
(s
)
S
c
o
t
P
h
o
t
E
-I
I:
2
/F
/3
6
/4
3
E
as
t
A
si
an
D
e
c
re
as
e
in
V
A
2
0
/3
3
2
0
/5
0
0
.2
5
0
.2
5
C
le
ar
G
ra
n
u
la
r
p
ig
m
e
n
t
al
te
ra
ti
o
n
s
in
th
e
m
ac
u
la
in
a
b
u
ll
’s
e
ye
p
at
te
rn
.
N
o
rm
al
as
p
e
c
t
o
f
th
e
o
p
ti
c
d
is
c
an
d
re
ti
n
al
ve
ss
e
ls
.
N
o
in
tr
ar
e
ti
n
al
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
.
SN
M
R
C
e
n
tr
al
sc
o
to
m
a
ar
M
D
p
.A
rg
1
9
3
3
*
p
.T
y
r1
3
5
2
A
la
fs
*9
F
-I
I:
3
/M
/5
0
/6
1
E
as
t
A
si
an
D
e
c
re
as
e
in
V
A
/
n
ig
h
t
b
li
n
d
n
e
ss
2
0
/6
3
0
2
0
/4
0
0
0
.5
0
2
.5
0
M
o
d
e
ra
te
c
o
rt
ic
al
an
d
m
il
d
n
u
c
le
ar
c
at
ar
ac
t;
ex
tr
ac
te
d
at
6
0
y
M
ac
u
la
r
at
ro
p
h
y,
m
il
d
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
ss
e
ls
,
n
u
m
m
u
la
r
h
yp
e
rp
ig
m
e
n
ta
ti
o
n
L
E
.
M
R
M
R
C
e
n
tr
al
sc
o
to
m
a
an
d
m
il
d
V
F
c
o
n
st
ri
c
ti
o
n
ar
C
R
D
p
.A
rg
1
9
3
3
*
p
.T
y
r1
3
5
2
A
la
fs
*9
G
-I
I:
2
/F
/3
7
/3
7
E
as
t
A
si
an
D
e
c
re
as
e
in
V
A
/
n
ig
h
t
b
li
n
d
n
e
ss
2
0
/5
0
2
0
/2
0
0
1
.2
5
1
.0
0
C
le
ar
M
ac
u
la
r
at
ro
p
h
y,
m
il
d
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
ss
e
ls
.
Sp
o
ra
d
ic
n
u
m
m
u
la
r
p
ig
m
e
n
ta
ti
o
n
in
L
E
.
SR
SR
C
e
n
tr
al
sc
o
to
m
a
an
d
V
F
c
o
n
st
ri
c
ti
o
n
(n
as
al
>
te
m
p
o
ra
l)
ar
C
R
D
p
.A
rg
1
9
3
3
*
p
.G
lu
3
3
4
fs
*2
2
H
-I
I:
2
/M
/1
4
/1
8
C
au
c
as
ia
n
D
e
c
re
as
e
in
V
A
2
0
/2
8
2
0
/5
0
3
.0
0
2
.0
0
C
le
ar
M
il
d
R
P
E
al
te
ra
ti
o
n
s
in
th
e
m
ac
u
la
.
P
e
ri
p
h
e
ry
n
o
rm
al
.
M
R
M
R
In
ta
c
t
p
e
ri
p
h
e
ra
l
V
F
ar
C
R
D
p
.P
ro
1
2
4
A
la
fs
*2
0
p
.V
al
1
9
0
G
ly
ar
R
P I-
II
:3
/F
/1
1
/1
3
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/2
5
2
0
/2
2
2
.1
3
1
.6
3
U
n
k
n
o
w
n
B
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
at
te
n
u
at
e
d
ve
ss
e
ls
,
p
al
lo
r
o
p
th
e
o
p
ti
c
d
is
c
,
an
d
p
e
ri
p
h
e
ra
l
at
ro
p
h
y.
N
R
SR
C
o
n
st
ri
c
te
d
V
F
to
1
0
–
1
5
8
ar
R
P
p
.I
le
1
6
8
A
sn
fs
*1
7
p
.L
y
s1
0
4
4
A
sn
fs
*1
6
J-
II
:2
/M
/6
/3
2
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/6
7
L
P
4
.0
0
4
.5
0
M
il
d
n
u
c
le
ar
c
at
ar
ac
t
M
ac
u
la
r
at
ro
p
h
y,
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
ss
e
ls
,
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
an
d
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
N
R
C
o
n
st
ri
c
te
d
V
F
<
1
0
8
ar
R
P
p
.T
y
r1
3
5
2
A
la
fs
*9
p
.T
y
r1
3
5
2
A
la
fs
*9
K
-I
I:
1
/M
/1
2
/4
6
E
as
t
A
si
an
N
ig
h
t
b
li
n
d
n
e
ss
H
M
H
M
1
.2
5
2
.0
0
P
SC
an
d
A
SC
;
ex
tr
ac
te
d
at
4
5
y
P
ro
fo
u
n
d
p
an
re
ti
n
al
d
e
ge
n
e
ra
ti
o
n
,
ab
u
n
d
an
t
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
an
d
se
ve
re
ly
at
te
n
u
at
e
d
ve
ss
e
ls
.
V
as
c
u
la
r
sh
e
at
h
in
g
L
E
.
N
P
N
P
C
o
n
st
ri
c
te
d
V
F
<
1
0
8
ar
R
P
p
.T
y
r1
3
5
2
A
la
fs
*9
p
.T
y
r1
3
5
2
A
la
fs
*9
L
-I
I:
2
/M
/1
0
/2
2
E
as
t
A
si
an
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/6
7
2
0
/5
0
5
.5
0
5
.2
5
C
o
n
ge
n
it
al
c
o
ro
n
ar
y
c
at
ar
ac
t
B
E
B
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
at
te
n
u
at
e
d
re
ti
n
al
ve
ss
e
ls
,
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
,
an
d
c
e
n
tr
al
R
P
E
al
te
ra
ti
o
n
s
w
it
h
sm
al
l
is
la
n
d
s
o
f
m
ac
u
la
r
at
ro
p
h
y.
SR
SR
C
o
n
st
ri
c
te
d
V
F
<
1
0
8
ar
R
P
p
.M
e
t5
0
0
fs
*3
3
p
.M
e
t5
0
0
fs
*3
3
M
-I
I:
2
/F
/5
/5
2
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
L
P
L
P
9
.0
0
8
.2
5
M
il
d
P
SC
,
m
il
d
c
o
rt
ic
al
an
d
n
u
c
le
ar
c
at
ar
ac
t
G
e
n
e
ra
li
ze
d
re
ti
n
al
d
ys
tr
o
p
h
y
w
it
h
m
ac
u
la
r
at
ro
p
h
y,
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
at
te
n
u
at
e
d
re
ti
n
al
ve
ss
e
ls
,
an
d
w
ax
y
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
(4
6
y)
N
R
(4
6
y
)
N
o
V
F
m
e
as
u
ra
b
le
ar
R
P
p
.P
ro
1
2
4
A
la
fs
*2
0
p
.P
ro
1
2
4
A
la
fs
*2
0
Macular and Cone-Rod Dystrophy Caused by RP1 Mutations IOVS j March 2019 j Vol. 60 j No. 4 j 1197
Downloaded from iovs.arvojournals.org on 05/27/2020
T
A
B
L
E
.
C
o
n
ti
n
u
e
d
ID
/S
e
x
/A
g
e
o
f
O
n
se
t,
y
/A
g
e
R
a
c
e
In
it
ia
l
S
y
m
p
to
m
V
is
u
a
l
A
c
u
it
y
R
E
L
E
S
E
R
†
R
E
L
E
L
e
n
s
S
ta
tu
s
O
p
h
th
a
lm
o
sc
o
p
y
R
e
su
lt
s
E
R
G
R
e
su
lt
s
G
o
ld
m
a
n
n
P
e
ri
m
e
tr
y
D
x
M
u
ta
ti
o
n
(s
)
S
c
o
t
P
h
o
t
ad
R
P
N
-I
II
:9
/F
/1
8
/5
6
E
as
t
A
si
an
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/5
0
2
0
/5
0
9
.3
8
1
0
.0
0
M
o
d
e
ra
te
n
u
c
le
ar
c
at
ar
ac
t;
ex
tr
ac
te
d
at
5
5
y
T
e
ss
e
ll
at
e
d
fu
n
d
u
s
w
it
h
R
P
E
at
ro
p
h
y
in
th
e
p
e
ri
p
h
e
ry
,
d
e
n
se
n
u
m
m
u
la
r
an
d
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
se
v
e
re
ly
at
te
n
u
at
e
d
re
ti
n
al
v
es
se
ls
,
an
d
w
ax
y
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
(5
1
y
)
N
R
(5
1
y
)
C
o
n
st
ri
c
te
d
V
F
to
1
0
8
w
it
h
a
sm
al
l
te
m
p
o
ra
l
re
si
d
u
e
ad
R
P
p
.L
e
u
7
6
2
T
y
rf
s*
1
7
O
-I
I:
1
/F
/
ch
il
d
h
o
o
d
/4
0
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/6
6
2
0
/4
0
5
.7
5
5
.5
0
M
il
d
c
at
ar
ac
t
P
ro
fo
u
n
d
at
ro
p
h
y
w
it
h
so
m
e
sp
ar
in
g
o
f
th
e
c
e
n
te
r,
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
at
te
n
u
at
e
d
re
ti
n
al
v
es
se
ls
,
an
d
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
(3
6
y
)
SR
(3
6
y
)
C
o
n
st
ri
c
te
d
V
F
to
1
0
8,
w
it
h
a
in
fe
ro
n
as
al
re
si
d
u
e
(R
E
)
an
d
te
m
p
o
ra
l
re
si
d
u
e
(L
E
)
ad
R
P
p
.L
e
u
7
6
2
T
y
rf
s*
1
7
P
-I
I:
1
3
/M
/4
0
/7
2
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/4
0
2
0
/6
3
þ1
.5
0
þ4
.0
0
M
o
d
e
ra
te
n
u
c
le
ar
c
at
ar
ac
t;
ex
tr
ac
te
d
at
7
0
y
P
ro
fo
u
n
d
(m
id
-)
p
e
ri
p
h
e
ra
l
at
ro
p
h
y,
ex
te
n
si
ve
b
o
n
e
sp
ic
u
le
an
d
n
u
m
m
u
la
r
p
ig
m
e
n
ta
ti
o
n
,
se
ve
re
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
ss
e
ls
,
an
d
w
ax
y
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
(7
1
y
)
N
R
(7
1
y
)
C
o
n
st
ri
c
te
d
V
F
to
1
5
8
(R
E
)
an
d
2
0
8
(L
E
)
ad
R
P
p
.S
e
r9
1
1
*
Q
-I
II
:4
/M
/2
5
/4
6
A
fr
ic
an
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/5
5
2
0
/4
6
4
.0
0
4
.0
0
E
x
tr
ac
te
d
at
3
4
y
P
ro
fo
u
n
d
b
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
s,
se
ve
re
at
te
n
u
at
io
n
o
f
re
ti
n
al
ve
ss
e
ls
,
p
e
ri
p
ap
il
la
ry
at
ro
p
h
y
an
d
so
m
e
(w
ax
y)
p
al
lo
r
o
f
th
e
o
p
ti
c
d
is
c
.
N
R
N
R
C
o
n
st
ri
c
te
d
V
F
to
5
8
(R
E
)
an
d
3
8
(L
E
)
ad
R
P
p
.A
rg
6
7
7
*
R
-I
V
:2
/M
/2
5
/3
5
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/2
0
2
0
/2
0
1
.2
5
2
.2
5
C
le
ar
B
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
in
th
e
m
id
p
e
ri
p
h
e
ry
(p
ar
ti
c
u
la
rl
y
n
as
al
re
ti
n
a)
,
m
il
d
at
te
n
u
at
io
n
o
f
th
e
re
ti
n
al
ve
ss
e
ls
,
n
o
rm
al
as
p
e
c
t
o
f
th
e
o
p
ti
c
d
is
c
.
M
il
d
E
R
M
ri
g
h
t
e
ye
.
N
P
N
P
C
o
n
st
ri
c
te
d
V
F
<
1
0
8
ad
R
P
p
.A
rg
6
7
7
*
S-
II
I:
4
/F
/2
3
/4
0
C
au
c
as
ia
n
N
ig
h
t
b
li
n
d
n
e
ss
2
0
/2
0
2
0
/3
4
3
.3
8
3
.3
8
C
le
ar
B
o
n
e
sp
ic
u
le
p
ig
m
e
n
ta
ti
o
n
,
at
te
n
u
at
e
d
re
ti
n
al
v
es
se
ls
,
g
e
n
e
ra
li
ze
d
re
ti
n
al
at
ro
p
h
y
w
it
h
fo
ve
al
sp
ar
in
g
.
N
R
SR
H
FA
3
0
–
2
:
c
e
n
tr
al
re
si
d
u
e
ad
R
P
p
.A
rg
2
5
Se
rf
s*
3
7
A
ll
fe
at
u
re
s
ar
e
p
re
se
n
t
sy
m
m
e
tr
ic
al
ly
,
u
n
le
ss
m
e
n
ti
o
n
e
d
o
th
e
rw
is
e
.
A
SC
,
an
te
ri
o
r
su
b
c
ap
su
la
r
c
at
ar
ac
t;
B
E
,
b
o
th
e
ye
s;
D
x
,
fi
n
al
d
ia
g
n
o
si
s;
E
R
M
,
e
p
ir
e
ti
n
al
m
e
m
b
ra
n
e
;
F,
fe
m
al
e
;
H
FA
,
H
u
m
p
h
re
y
fi
e
ld
an
al
yz
e
r;
H
M
,
h
an
d
m
o
ve
m
e
n
ts
;
L
E
,
le
ft
e
ye
;
L
P,
li
g
h
t
p
e
rc
e
p
ti
o
n
;
M
,
m
al
e
;
M
R
,
m
o
d
e
ra
te
ly
re
d
u
c
e
d
;
N
,
n
o
rm
al
;
N
P,
n
o
t
p
e
rf
o
rm
e
d
;
N
R
,
n
o
n
re
c
o
rd
ab
le
;
P
h
o
t,
p
h
o
to
p
ic
;
P
SC
,
p
o
st
e
ri
o
r
su
b
c
ap
su
la
r
c
at
ar
ac
t;
R
E
,
ri
g
h
t
e
ye
;
SE
R
,
sp
h
e
ri
c
al
e
q
u
iv
al
e
n
t
re
fr
ac
ti
o
n
;
Sc
o
t,
sc
o
to
p
ic
;
SN
,
su
b
n
o
rm
al
;
SR
,
se
ve
re
ly
re
d
u
c
e
d
;
V
A
,
v
is
u
al
ac
u
it
y;
V
F,
v
is
u
al
fi
e
ld
.
†
If
c
at
ar
ac
t
su
rg
e
ry
h
as
b
e
e
n
p
e
rf
o
rm
e
d
,
th
e
p
re
o
p
e
ra
ti
ve
sp
h
e
ri
c
al
e
q
u
iv
al
e
n
t
w
as
re
p
o
rt
e
d
.
Macular and Cone-Rod Dystrophy Caused by RP1 Mutations IOVS j March 2019 j Vol. 60 j No. 4 j 1198
Downloaded from iovs.arvojournals.org on 05/27/2020
night blindness in all cases and all patients were myopic (range
of spherical equivalents: 9.00 D to 1.63 D; Table, Supple-
mentary Table S3). Despite their young age, all four patients for
whom data were available already showed lens opacities at a
mean age of 33 years. The visual acuity deteriorated from
adolescence or early adulthood to levels of light perception in
the sixth decade of life and constriction of the visual field with
a residue of less than 10 degrees at the most recent
examination was present in three of four patients (Table, Fig.
2).
Ophthalmoscopy showed the three hallmark RP signs—
bone spicule pigmentations, attenuation of the retinal vessels,
and pallor of the optic disc—often accompanied by profound
peripheral RPE atrophy. In addition, macular atrophic lesions
were present in four of five patients, with sparing of the fovea
in two of them (Table). This was confirmed by an intact
ellipsoid zone layer in the fovea on SD-OCT (Fig. 3R,
Supplementary Table S3). Finally, ERG responses were severely
reduced or nonrecordable under scotopic and photopic
conditions in all RP patients.
Autosomal Dominant RP
Patients with adRP presented with night blindness, at a mean
age of 26.2 years (SD 8.2; range 18–40 years). Five of six
patients were myopic (range of spherical equivalents: 10.00
toþ4.00), except for patient O-II:13, who was hyperopic with
spherical equivalents of þ1.50 D and þ4.00 D (Table).
Biomicroscopy revealed several types of lens opacities in four
of six patients of whom three patients underwent cataract
extraction (Table, Supplementary Table S3). The visual acuity
was relatively preserved, as all patients retained a visual acuity
of 20/80 or better, even at the age of 72 (patient O-II:13) (Fig.
2, Supplementary Table S3). However, the visual field showed
severe constriction with a central residue of less than 10
degrees in two of six patients at a mean age of 48 years (Table,
Supplementary Table S3).
The patients with adRP also showed bone spicule pigmen-
tation and attenuation of the retinal vessel, often accompanied
by profound peripheral RPE atrophy and macular atrophy in
four of six patients (Table). However, the fovea was spared
from the atrophic lesions in all patients (except for the left eye
of patient O-II:1). Patient O-II:1 previously underwent a pars
plana vitrectomy with peeling of the internal limiting
membrane in both eyes for macular holes. Cystoid macular
edema was present in patient Q-III:4, with a moderate
response to oral carbonic anhydrase inhibitors. Finally, ERG
responses were nonrecordable under scotopic conditions and
severely reduced or nonrecordable under photopic conditions.
DISCUSSION
Mutations in the RP1 gene have previously been described in
patients with adRP and arRP. In the present study, we provide a
detailed clinical description of these phenotypes and report
two additional RP1-associated diagnoses: arMD and arCRD,
which may represent a single spectrum of retinal degeneration.
The patients with RP1-associated arMD/arCRD presented
with a decrease in visual acuity or metamorphopsia, generally
first noticed in the fourth decade, which eventually progressed
to legal blindness. Considerable macular abnormalities were
observed at the most recent examination including a bull’s eye
maculopathy in two patients. This bull’s eye maculopathy may
eventually progress to macular atrophy with foveal involve-
ment, as was observed in patient A-II:5. Unfortunately,
longitudinal data of the other patients to confirm this
hypothesis were not available.
MD and CRD may show large overlap in clinical and genetic
findings. This overlap also occurs in time: an MD phenotype
FIGURE 2. Graph showing the course of visual acuity over time in patients with mutations in the RP1 gene. The three phenotypes are indicated
with different colors: arMD/arCRD in blue, arRP in orange, and adRP in red. The visual acuity of the best eye is displayed. Snellen visual acuity was
converted into logMAR. A logMAR value of 1.9 was assigned to counting fingers (CF), 2.3 to hand movements (HM), and 2.7 to light perception (LP).
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FIGURE 3. Multimodal images of patients with mutations in RP1. (A–C) Multimodal images of the left eye of patient A-II:4. (A) Composite fundus
photograph showing a well-demarcated area of chorioretinal atrophy involving the fovea. (B) This area corresponds with an oval zone of absent FAF,
bordered by a small residual band of increased FAF. (C) SD-OCT scan revealing loss of the outer retinal layers in the macula. (D–F) Multimodal
imaging of the left eye of patient B-II:3. (D) Composite fundus photograph showing macular atrophy, attenuated retinal vessels, and no
hyperpigmentation. (E) FAF image revealing decreased autofluorescence surrounded by a hyperautofluorescent ring. (F) SD-OCT scan showing
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can eventually progress to a more generalized disorder and
converge into a CRD phenotype. This may explain the
intrafamilial differences in family B, as patient B-II:8 shows
abnormalities limited to the macular region, whereas her older
sister displays generalized disease, which may represent a later
disease stage. It might also explain the more severe phenotype
in patient F-II:3, who carries the same mutations as the younger
patients C to E with less severe disease. In addition, the mean
age of onset of both phenotypes was the same (P ¼ 0.817).
Therefore, arMD and arCRD might represent the longitudinal
progression of macular/cone predominant RP1-associated
disease. Nevertheless, some patients may never show progres-
sion to a CRD phenotype and other (genetic) modifiers may
also exert their effect on the final phenotype. Because the
focus of our manuscript lies on the description of patients with
a phenotype that does not match the existing phenotypes with
predominant rod involvement, we have combined them into
the all-embracing term ‘‘arMD/arCRD.’’
The arMD/arCRD shows similarities with other MDs (e.g.,
central areolar choroidal dystrophy and Stargardt disease),
multifocal pattern dystrophy simulating Stargardt disease, and
cone dystrophies, and, because of its later age of onset, can
mimic AMD.16–18 It is, however, important to distinguish these
disorders to provide the patient with valuable and correct
prognostic information and accurate treatment. An adequate
family history, the absence of drusen, and the symmetrical
presentation of the macular atrophy can help the clinician in
distinguishing hereditary forms of MDs from AMD.17 The
absence of irregular yellowish (pisciform) and/or hyperauto-
fluorescent flecks can help to differentiate RP1-associated
disease from Stargardt disease, pseudo-Stargardt, and certain
cases of central areolar choroidal dystrophy, and ERG
responses can help to differentiate from cone dystrophies.
The phenotype of the RP patients was in accordance with
earlier reports on RP caused by RP1 mutations in literature.
The five patients with arRP experienced night blindness in the
first or second decade of life and showed early involvement of
the macular region, whereas the age of onset in the six patients
with adRP was between the second and fourth decades, and
the fovea remained relatively intact during the course of the
FIGURE 4. Multimodal images of the left eye of patient A-II:5 over an interval of 6 years. (A) Fundus photograph showing a bull’s eye maculopathy,
some peripapillary atrophy, and a normal aspect of the optic disc and retinal vessels. (B) The FAF image reveals an oval area of
hyperautofluorescence containing a ring of hyper- and hypoautofluorescence. (C) Horizontal SD-OCT showing perifoveal loss of the outer retinal
layers. (D) Fundus photograph 6 years later showing macular atrophy, and (E) FAF showing the corresponding area of hypoautofluorescence
surrounded by a zone of increased autofluorescence. (F) The OCT scan shows the loss of the outer retinal layers that now also involves the fovea.
preservation of the RPE, ellipsoid zone, and external limiting membrane layer in the fovea, and an epiretinal membrane. (G–I) Multimodal imaging
of the left eye of patient B-II:8, at the age of 55 years. (G) Fundus photograph showing a bull’s eye maculopathy, a normal aspect of the optic disc
and vasculature, and no intraretinal hyperpigmentation. (H) FAF shows a corresponding oval area of speckled hyper- and hypoautofluorescence,
surrounded by a ring of hyperautofluorescence. (I) SD-OCT image revealing the parafoveal loss of outer retinal layers with preservation of the
ellipsoid zone and external limiting membrane layer in the fovea. (J–L) Multimodal imaging of the right eye of patient D-II:1. (J) Ultra-widefield
fundus photograph showing RPE alterations in the macula, peripapillary atrophy, no hyperpigmentations, and a normal aspect of the optic disc and
retinal vessels. (K) Ultra-widefield FAF image showing a speckled pattern of hyper- and hypoautofluorescence, surrounded by a band of increased
FAF. (L) OCT scan showing generalized loss of photoreceptor inner and outer segments, and an epiretinal membrane. (M–O) Multimodal imaging of
the left eye of patient J-II:2. (M) Ultra-widefield fundus photograph showing RPE atrophy, bone spicule pigmentation, and attenuation of the retinal
vessels. (N) Autofluorescence image revealing decreased autofluorescence in the macula and along and surrounding to the vascular arcades. (O) SD-
OCT scan showing generalized loss of the outer retinal layers in the macula. (P–R) Multimodal imaging of the left eye of patient N-III:9. (P)
Composite fundus photograph showing profound peripheral atrophy, severe attenuation of retinal vessels, extensive bone spicule and nummular
pigmentation, and waxy pallor of the optic disc. (Q) FAF image showing a hyperautofluorescent ring in the macula, surrounded by a speckled
pattern of hyper- and hypoautofluorescence, and nummular areas of decreased macular and peripheral autofluorescence. (R) SD-OCT scan revealing
the preservation of the photoreceptor layer at the fovea.
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disease.1,2 Myopia, in varying degrees, is a common feature,
and was found in 96% of patients. This association of myopia
and RP1-related disease has previously been described,
particularly in arRP patients.19,20
Together, these four retinal dystrophies now form the
spectrum of RP1-associated disease. It is, however, important
to realize that the RP phenotypes are not simply a more
extensive form of the more centrally located form of RP1-
associated disease. This is illustrated by the visual acuity in the
adRP patients that can remain relatively preserved even in
advanced RP cases as well as the different predominantly
affected photoreceptors
The phenotype is, to a large extent, determined by the
location and severity of the mutations in the RP1 gene. Several
classifications of mutations have been proposed.7,21,22 In
Supplementary Figure S1, we provide the latest overview of
mutations and their location. The mutations responsible for
adRP reside in a hotspot region in exon 4 between amino acid
residues 500 and 1053, and are expected to result in a
truncated protein with dominant-negative activity.8 In contrast,
arRP is caused by the presence of two nonsense or frameshift
mutations in RP1. Patients with arMD/arCRD carry a hetero-
zygous variant that is expected to have a mild effect on protein
function (p.Phe180Cys, p.Val190Gly, or p.Arg1933*) in combi-
nation with a more severe nonsense or frameshift mutation, or
a combination of two predicted mild variants such as
p.Gln1916* and p.Arg1933* in family 1 and the compound
heterozygous missense variants (p.Tyr41His and p.Leu172Arg)
reported by Ellingford et al.9 in a single MD patient (Fig. 1). The
p.Arg1933* variant, a recurrent variant in the Japanese
population (allele frequency: 0.6%), does not cause a retinal
dystrophy in homozygous carriers, at least not before the age of
80 years.10 Although, in combination with a pathogenic
variant, such as p.Glu334fs*22, p.Tyr1352Alafs*9, or another
likely hypomorphic variant p.Gln1916*, the effect of this
hypomorphic allele seems to be sufficient to cause retinal
disease (Fig. 1).
Although these findings are consistent within our study,
there are reports, albeit with limited clinical information, that
conflict with our findings. For example, p.Arg1933* was found
in trans with the p.Tyr834* nonsense variant in a patient with
arRP.23 In addition, other previously reported variants, such as
p.D202E, p.I1988Nfs*3, and p.I2061Sfs*12, could also be
predicted to be mild or hypomorphic variants considering
their location; however, they have been associated with arRP,
although the clinical phenotype has not been described in
detail.23–25 The explanation for this clinical heterogeneity
remains to be elucidated, but might be explained by additional
(genetic-) modifying factors, the presence of a structural
variant or a variant in the non-coding regions of RP1,
pathogenic variants in another RP gene, or inaccurate
phenotyping, the latter of which should be considered
particularly in advanced RP and CRD, in which the distinction
can be difficult and depends on patients’ self-reported disease
course. A potential genetic modifier for RP1-associated disease
may be RP1L1, because these proteins have synergistic roles in
the photoreceptor axoneme.26 However, we did not find any
rare variants in the RP1L1, although intronic or structural
variants cannot be excluded (Supplementary Table S2).
RP1 is an interesting candidate for gene therapy, because of
its relatively high prevalence in RP.1 However, important
challenges must be overcome before gene therapy for RP1 can
reach the clinic. For example, knowledge about the natural
course of the disease is required to be able to evaluate
treatment efficacy, particularly in view of the different
phenotypes. In addition, in case of gene augmentation therapy,
the maximum cargo capacity of the AAVs (~4.7 kb) is too
limited to fit the RP1 gene (6.5 kb),27,28 and the optimal
expression levels of the RP1 protein need to be determined.8
This could be more important than previously anticipated if
our hypothesis that a hypomorphic variant in combination
with a deleterious variant causes arMD/arCRD is correct.
Insufficient dosage of the RP1 gene by gene transfer may
mimic this condition and could in that case result in the
development of an iatrogenic MD. Obviously, this would be a
serious concern when treating arRP patients with preserved
macular function with the goal to halt the progression of
central visual field loss. Although patients with adRP might also
benefit from an elevation of wild-type RP1 levels,8 the mutant
protein that possesses dominant-negative activity remains
present in the cell and competes with the wild type. Therefore,
other genetic therapies, such as treatment with antisense
oligonucleotides, of which proof-of-concept has been shown in
an animal model with RHO-associated RP,29 or genome editing
may be alternative approaches.
In conclusion, mutations in the RP1 gene can lead to
different clinical phenotypes, varying from RP to arMD/
arCRD, depending on the residual RP1 function. Together,
these dystrophies form a spectrum of RP1-associated
phenotypes that can be clinically distinguished from each
other based on the clinical findings, inheritance pattern, age
of onset, and disease course. However, additional longitudi-
nal studies are essential to improve the diagnostic process
and to study the role of potential modifiers. With the advent
of novel therapeutic options such as gene therapy, recogni-
tion of the entire clinical spectrum associated with RP1
mutations is essential to aid the selection of patients eligible
for treatment, and to evaluate the effect of the treatment
provided.
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